Trillium Therapeutics
0
0
+€0.00+0% 00:00 Hari ini
Statistik
Tertinggi harian
-
Paras terendah hari ini
-
Tertinggi 52M
-
Paras terendah 52M
-
Volum
-
Vol. purata
-
Kap. pasaran
0
Nisbah P/E
-
Hasil dividen
-
Dividen
-
Pesaing
Senarai ini adalah analisis berdasarkan peristiwa pasaran terkini. Ia bukan cadangan pelaburan.
Perihal
Trillium Therapeutics Inc., a clinical stage immuno-oncology company, develops therapies for the treatment of cancer. Its include TTI-622, a SIRPa-IgG4 Fc fusion protein that is designed to enhance macrophage-mediated phagocytosis and anti-tumor activity by blocking the CD47, which is in Phase 1 clinical trials; and TTI-621, a SIRPa-IgG1 Fc fusion protein, which is in Phase 1 clinical trials and generates a signal blocking the CD47 for advanced relapsed or refractory hematologic malignancies, and solid tumors and mycosis fungoides. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was incorporated in 2004 is based in Mississauga, Canada.
Tunjukkan lagi
CEO
Dr. Jan Skvarka
Pekerja
33
Negara
Kanada
ISIN
CA89620X5064
Penyenaraian
0 Komen
Kongsi pendapat anda
Soalan Lazim
Apakah simbol saham Trillium Therapeutics?▼
Bergantung pada bursa, simbol saham mungkin berbeza. Sebagai contoh, di bursa Boerse Stuttgart, saham Trillium Therapeutics didagangkan di bawah simbol R5WP.STU.
Berapa ramai pekerja yang dimiliki oleh Trillium Therapeutics?▼
Sehingga 1 November 2026, syarikat mempunyai 33 pekerja.
Trillium Therapeutics terletak dalam sektor apa?▼
Trillium Therapeutics beroperasi dalam sektor Kesihatan & Kesejahteraan.
Bilakah Trillium Therapeutics menyiapkan split saham?▼
Trillium Therapeutics tidak mempunyai sebarang split baru-baru ini.
Di manakah ibu pejabat Trillium Therapeutics?▼
Ibu pejabat Trillium Therapeutics terletak di Mississauga, Kanada.